Details for New Drug Application (NDA): 020896
✉ Email this page to a colleague
The generic ingredient in XELODA is capecitabine. There is one drug master file entry for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the capecitabine profile page.
Summary for 020896
| Tradename: | XELODA |
| Applicant: | Cheplapharm |
| Ingredient: | capecitabine |
| Patents: | 0 |
Pharmacology for NDA: 020896
| Mechanism of Action | Nucleic Acid Synthesis Inhibitors |
Medical Subject Heading (MeSH) Categories for 020896
Suppliers and Packaging for NDA: 020896
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| XELODA | capecitabine | TABLET;ORAL | 020896 | NDA | H2-Pharma, LLC | 61269-475 | 61269-475-12 | 120 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (61269-475-12) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 150MG | ||||
| Approval Date: | Apr 30, 1998 | TE: | RLD: | Yes | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 500MG | ||||
| Approval Date: | Apr 30, 1998 | TE: | RLD: | Yes | |||||
Expired US Patents for NDA 020896
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Cheplapharm | XELODA | capecitabine | TABLET;ORAL | 020896-001 | Apr 30, 1998 | ⤷ Start Trial | ⤷ Start Trial |
| Cheplapharm | XELODA | capecitabine | TABLET;ORAL | 020896-002 | Apr 30, 1998 | ⤷ Start Trial | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
